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Introduction
Branched-chain fatty acids are common in the diet and similar structures
are found in medicines such as Ibuprofen and related drugs. Metabolism of
branched-chain fatty acids requires that the centres bearing the methyl
groups possess S-stereochemical configuration, but those with R-
configuration are produced in the body and are found in the diet. Ibuprofen
and related drugs require S-configuration for their anti-inflammatory
properties, but these drugs are usually given as a mixture of R- and S-
enantiomers. The enzyme α-methylacyl-CoA racemase (AMACR)
catalyses R- to S- conversion of 2-methylacyl-CoA derivatives of fatty
acids enabling β-oxidation. Similarly, acyl-CoA derivatives of Ibuprofen and
similar drugs are converted, resulting in pharmacological activation.1,2
AMACR levels are increased in all prostate cancers, some colon cancers
and other cancers.1-3 In prostate cancer, higher AMACR levels result in
higher proliferation rates4 and androgen-independent growth5 and AMACR
is recognised as a novel drug target. However, few inhibitors have been
identified, largely due to the difficulties in measuring enzyme activity which
makes it difficult to quantify drug potency.1 AMACR catalyses the
irreversible elimination of hydrogen fluoride from 3-fluoro-2-methylacyl-
CoA substrates,6 but translating this reaction to a convenient colorimetric
or fluorometric assay has proven difficult.3 4-Nitrophenol derivatives are
commonly used as colorimetric substrates for enzymes. This study reports
the synthesis of a 2,4-dinitrophenol-containing AMACR substrate and the
characterisation of known AMACR inhibitors using a convenient
colorimetric microtitre plate assay.
Results and Discussion
2,4-Dinitrophenol is fully ionised at neutral pH giving a yellow colour and
has a similar pKa to HF, which is eliminated from known AMACR
substrates. Therefore an acyl-CoA derivative 1 containing 2,4-dinitrophenol
was investigated. Reaction of 2 with alcohol 3 to give 4 followed by
oxidation gave the racemic acid 5, which was converted to the desired
substrate 1 (Scheme 1). Incubation of 1 with recombinant human AMACR
1A resulted in formation of unsaturated product 6 and 2,4-dinitrophenol 7
resulting in a yellow colour.
Scheme 1: Synthesis of novel substrate 1 and reaction with AMACR.
Reagents & conditions: i. Na metal; ii. Jones oxidation; iii. CDI, DCM; iv.
CoA-SH, NaHCO3 aq./THF (1:1); v. NaH2PO4-NaOH, pH 7.4, ca. 77%
2H2O.
AMACR was active around neutral pH and retained full activity in the
presence of 8% (v/v) DMSO. Kinetic analysis of substrate 1 showed that
Michaelis-Menten kinetics were observed (Figure 1), with the following
parameters: Km = 56 ±4.5 µM; Vmax = 112 ± 4 nmol.min.
-1mg-1; kcat =
0.088 s-1; kcat/Km = 1571 s
-1 M-1. This shows that substrate 1 is converted
with ~44% of the efficiency of 3-fluoro-2-methyldecanoyl-CoA and was
significantly more efficient than ‘racemisation’ of 2-methyldecanoyl-CoA (as
judged by kcat/Km).
6
Figure 1: Kinetic analysis for substrate 1.
The known inhibitor Rose Bengal7 was tested to validate the method for
characterisation of inhibitors (Figure 2). A dose-response curve was
efficiently produced using a microtitre plate assay.
Figure 2: AMACR inhibition assay using Rose Bengal as an inhibitor. A. 96-
Well plate showing colour change; B. Dose-response curve for Rose
Bengal.
A number of other known AMACR inhibitors and substrates were tested
using a dose-response curve at a fixed substrate concentration of 40 µM.
Ibuprofenoyl-CoA and related compounds are known substrates and should
behave as competitive inhibitors. All of these compounds inhibited the
enzyme with IC50 values of ca. 300-500 nM. 2-Methyldecanoyl-CoA also
inhibited the reaction, and was ca. 4x more potent than decanoyl-CoA.
Inhibition was decreased in acyl-CoA esters with shorter alkyl chains. The
best acyl-CoA inhibitor was N-dodecyl-N-methylcarbamoyl-CoA,8 which was
~500 – 1000 x more potent than the other acyl-CoA inhibitors (as judged by
IC50 values). The non-specific protein modifying reagents reported by Wilson
et al.7 also inhibited the enzyme; in contrast to previous reports Ebselen
behaved as a time- and concentration-dependent inactivator with a rate
constant of 114 M-1 s-1.
Figure 3: Selected acyl-CoAs and protein modifying agents shown to inhibit
the conversion of substrate 1 to 6 and 7 by AMACR using the colorimetric
assay.
Conclusions
The colorimetric substrate 1 provides a convenient method for assaying
AMACR and determining the behaviour and potency of inhibitors. AMACR
is a promising drug target for prostate and other cancers, but until now it has
been under-exploited because of the difficulties in determining enzyme
activities. Inhibitors previously reported in the literature are largely limited to
rationally designed acyl-CoA esters, which do not comply with Lipinski
guidelines.9 This new assay will facilitate the testing and development of
drugs by structure-based design, rational design and lends itself to
screening approaches. The latter should allow identification of inhibitors with
good drug-like properties.
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